This Pilot Study is to investigate the tear proteins in a multitude of cancer types and indulge in biomarker discovery to manufacture simple, accurate, and novel tear-based diagnostic tests.
The Pilot Study is an observational study to investigate the diagnostic potential of tear proteins for Breast, Ovarian, Prostate, Melanoma, Pancreatic, and Colon cancer. In this pilot study, we use lacrimal gland fluid (tears) as a liquid biopsy source for investigating the protein repertoire and conducting biomarker discovery studies with a goal to develop new tear-based tests that can detect crucial cancer-related biomarkers in the pan-cancer types. Proteomic studies on tears have shown to express between 500-1500 proteins with \~35% overlap with serum proteome. The easy accessibility of tear fluid with minimal post-processing procedures and better access to lower molecular weight proteins make tears an ideal source to identify commonly associated cancer biomarkers. Additionally, the results from this study will aid in improving our understanding of the cancer types and commonalities that exist between them.
Study Type
OBSERVATIONAL
Enrollment
500
Schirmer strip is a Class I Medical Device typically used to test for dry eye and will be used to collect lacrimal tear fluids.
Namida Lab
Fayetteville, Arkansas, United States
Identify Cancer-related Biomarkers
A tear protein repertoire will be created to identify key cancer biomarkers
Time frame: Dec 2023
Tear Protein Concentrations
The total protein concentrations will be measured at different temperature conditions to determine the protein degradation profiles.
Time frame: Dec 2023
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.